
Sri Lanka Cancer Registry 16th Publication

CANCER INCIDENCE & MORTALITY DATA SRI LANKA 2014



National Cancer Incidence and Mortality Data

Sri Lanka 2014



National Cancer Control Programme

Ministry of Health 555/5 Public Health Complex Elvitigala Mawatha, Narahenpita, Colombo 05 Sri Lanka 16th Publication – National Cancer Incidence and Mortality Data Sri Lanka: 2014

Published in March 2021

Acknowledgements

National Advisory Committee on Prevention & Control of Cancers

World Health Organization- Country Office, Sri Lanka

Cancer Care Association - Sri Lanka

Compiled by

Strategic Information and Management (SIM) Unit National Cancer Control Programme Sri Lanka

Published by



National Cancer Control Programme Ministry of Health 555/5 Public Health Complex Elvitigala Mawatha, Narahenpita, Colombo 05 Sri Lanka

Contact No +94 112368627, Fax +94 112368627 Email- <u>nccpsl@yahoo.com</u> Web – <u>www.nccp.health.gov.lk</u>

facebook

National Cancer Control Programme, Sri Lanka

Executive Summary

'Cancer Incidence & Mortality Data Sri Lanka – 2014' is the 16th volume of the series of publication on cancer surveillance data of Sri Lanka. This is the output report of National Cancer Registry / Sri Lanka Cancer Registry (SLCR) based on newly reported cancers in the year 2014. The newly detected cancers through the government cancer treatment centres, pathology laboratories, Oral and Maxillo-Facial (OMF) surgery units in the country were considered for this publication. As a new initiative of cancer surveillance from year 2012, the Population Based Cancer Registry (PBCR) of Colombo district was also commenced. The additional data sources considered for the Population Based Cancer Registry initiative in Colombo district were also incorporated to the national cancer registry database. All the data were entered into the CanReg 5 database. When processing the data, quality checks were conducted and duplicate entries were eliminated. Analysis was conducted using Can Reg 5 software and SPSS software.

In the year 2014, a total of 25,271 new patients with cancers were reported, giving a crude incidence rate (CR) of 121.6 per 100,000. Crude incidence rates of males and females were 119.5 /100,000 (n=12,021) and 123.6/100,000 (n=13,250). The highest 5-year age specific incidence rates were reported among males of 70-74 age group (803.3/100,000) and females of 70-74 age group (514.2/100,000). When age standardized rates (ASR) were considered, the overall ASR was 107.3 /100,000 and the ASR for males and females were 112.0/100,000 and 105.3 /100,000 respectively.

Lip, tongue & mouth (n=1923, ASR=17.6/100,000), Lung (n=1156, ASR = 10.7/100,000), Oesophagus (n=903, CR = 8.3/100,000) and Colon & rectum (n=800, CR=7.4/100,000) were the highest incident cancers among males. Out of all reported cancers among males, 16% of cancers were Lip, tongue and mouth cancers.

Breast (n=3291, ASR =26.0/100,000), Thyroid (n=1432, ASR = 11.8 /100,000), Cervix (n=1090, ASR =8.5 /100,000) and Colon & rectum (n=965, CR=7.5/100,000) were the highest incident cancers among females. Thyroid cancer remained the second commonest cancer among females pushing cervical cancer into third position as in year 2013. Out of all cancers reported among females, 25% of cancers were breast cancers.

Among children and adolescents, the most common cancer was (i) Leukemias, myeloproliferative diseases and myelodysplastic diseases (n=229), while (ii)lymphomas(n=80), (iii) CNS neoplasms (n=70), (iv) neuroblastomas and other peripheral nervous cell tumors (29) had positioned next in the list respectively.

Mortality data received through Department of Census & Statistics was evaluated. A total of 7,459 (Crude death rate 74.2/100,000) and 6,055 (Crude death rate 56.5/100,000) cancer related deaths were reported among males and females respectively in the year 2014. Age specific death rates among females were lower than males and death rates were increasing over the advanced age. Malignant neoplasm of trachea, bronchus and lung was the leading cause of death among males and cancer of the breast was the leading cause of death among females.

Table of Contents

	Page No
Acknowledgements	3
Executive Summary	4
Table of Contents	5
List of Tables	6
List of Figures	7
Introduction	8
Methodology	9
Cancer Incidence Data of Sri Lanka – Tables and Figures	15
Mortality of Cancers	43

List of Tables

Table	No Description	Page No
Section	1 – Cancer Incidence Data of Sri Lanka, 2014	
01	Population of Sri Lanka: sex distribution 2006 – 2014	15
02	Cancer incidence by sex in Sri Lanka, 2006 – 2014	16
03	Cancer incidence by 5-year age groups and sex in Sri Lanka, 2014	19
04	Leading cancer sites by sex in Sri Lanka, 2014	20
05	Cancer cases by 5-year age group among Males in Sri Lanka, 2014	22
06	Cancer cases by 5-year age group among Females in Sri Lanka, 2014	26
07	Number of incidence cancers by five-year age group and	
	site among Males in Sri Lanka, 2014	31
08	Number of incidence cancers by five-year age group and	
	site among Females in Sri Lanka, 2014	32
09	Age specific incidence rate, Crude incidence rate, Age standardized incidence rate per 100,000 population & Cumulative risk of cancers by five-year age group and site among Males in Sri Lanka, 2014	33
10	Age specific incidence rate, Crude incidence rate, Age standardized incidence rate per 100,000 population & Cumulative risk of cancers by five-year age group and site among Females in Sri Lanka, 2014	34
11	Childhood & Adolescent (0-19) Cancer Incidence Data according to International Childhood Cancer Classification (ICCC-3)	35
Section	2 – Cancer Mortality Data of Sri Lanka 2014	
12	Deaths due to cancers at the government hospitals in Sri Lanka, 2005-2014	40
13	Deaths due to cancers out of all registered deaths in hospitals & field in Sri Lanka, 2001 – 2014	41
14	Proportion of deaths due to cancers occurred at the hospitals out of total cancer deaths	41
15	Deaths due to cancers out of all registered deaths by sex in hospitals & field in Sri Lanka, $2001 - 2014$	42
16	Leading sites (ICD-10) of cancer mortality – Male Sri Lanka 2014	43
17	Leading sites (ICD-10) of cancer mortality – Female Sri Lanka 2014	43

List of Figures

Table	e No Description	Page No
Section	n 1 – Cancer Incidence Data of Sri Lanka 2014	
01	General population in Sri Lanka by 5-year age groups in year 2014 (Population Pyramid)	15
02	Crude Cancer Incidence Rates in Sri Lanka, 2006 – 2014	17
03	Age Standardized Cancer Incidence Rates in Sri Lanka, 2006 – 2014	17
04	Cancer Incidence Rates in Sri Lanka – 2014	18
05	Age Specific Cancer Incidence rates in Sri Lanka – 2014	18
06	Proportion of leading cancers in Males in Sri Lanka – 2014	21
07	Proportion of leading cancers in Females in Sri Lanka – 2014	21
Section	n 2 – Cancer Mortality Data of Sri Lanka 2014	
08	Age Standardized mortality rates due to cancer in Sri Lanka, 2001 – 2015	42
09	Age standardized leading cancer mortality rates in males in Sri Lanka, 2010 – 2014	4 44
10	Age standardized leading cancer mortality rates in females in Sri Lanka, $2010 - 20$	014 44
11	Age standardized Trachea, bronchus & lung cancer mortality rates	45
	of Sri Lanka, 2010 – 2014	
12	Age standardized Lip, oral cavity & pharyngeal cancer mortality	45
	Rates of Sri Lanka, 2010 – 2014	
13	Age standardized Breast cancer mortality rates of Sri Lanka, 2010 – 2014	46
14	Age standardized Oesophageal cancer mortality rates	46
	of Sri Lanka, 2010 – 2014	
15	Age standardized Colon, rectal and anal cancer mortality rates	47
	of Sri Lanka, 2010 – 2014	
16	Age standardized Prostate cancer mortality rates of Sri Lanka, 2010 – 2014	47
17	Age standardized Cervical cancer mortality rates of Sri Lanka, 2010 - 2014	48

Cancer Incidence & Mortality Data Sri Lanka – 2014

1. Introduction

Cancer surveillance (Cancer registration) is a process of systematic, continuous collection, storage, analysis, interpretation and dissemination of epidemiological information on cancers occurring in a country or a specific geographic area. Information generated from the cancer registration is essential for planning, implementation, monitoring and evaluation of cancer control activities of the country.

The National Cancer Control Programme (NCCP) of the Ministry of Health coordinates surveillance of cancers in Sri Lanka with the active participation of other stakeholders for cancer surveillance including cancer treatment centres, pathology laboratories, Oral and Maxillo Facial (OMF) units, professional colleges, WHO country office etc. The process of surveillance of cancers is technically guided by the International Agency for Research on Cancer (IARC) of WHO and WHO IARC Regional Hub for Cancer Registration, Mumbai India. In addition, technical guidance is received from Department of Epidemiology, Bis statistics and Cancer Registry, WIA Cancer Institute, Chennai India.

The information based on surveillance of cancers is published as a publication named 'Cancer Incidence Data Sri Lanka'. Up to now 15 volumes have been published as shown in Table i. This publication is the 16th volume of Cancer Incidence & Mortality Data Sri Lanka. **Table (i) Summary details of previous publications of 'Cancer Incidence Data Sri Lanka'**

Year of		Dat	ta genera	ting centres	5		Pub	lication
cancer incidence	Cancer Treatment	Pathology laboratori	OMF units	Medical Record	Death Registrar	Total no. of	Volume	Year published
data	Centres	es		Rooms	S	centres		
1985	3	_	_	_	_	3	1	1990
1986	3	_	_	_	_	3	2	1991
1987	3	_	_	_	_	3	3	1993
1990	3	_	_	_	_	3	4	1996
1995	3	_	_	_	_	3	5	2002
2000	4	_	_	_	_	4	6	2006
2001-2005	5	_	_	_	_	5	7	2009
2006	6	_	4	_	_	10	8	2012
2007	6	_	4	_	_	10	9	2013
2008	7	16	17	_	_	40	10	2014
2009	9	15	17	_	_	41	11	2015
2010	9	13	17	_	_	39	12	2016
2011	9	13	12	-	-	34	13	2018
2012	9	37	15	9	40	110	14	2020
2013	9	45	15	25	40	134	15	2021

2. Methodology Cancer Incidence Data

The methodology of surveillance for cancer incidence data includes (i) collection of cancer incidence data from the point of diagnosis /from the point of treatment, (ii) coding of cancer incidence data, (iii) entering of cancer incidence data to the database, (iv) duplicate checking & verification of data, (v) analysis of data and (vi) dissemination of information through the publication of 'Cancer Incidence Data Sri Lanka' and other modes.

The methodology of each step of cancer surveillance is described below.

2.1.1 Collection of cancer incidence data

Cancer incidence data were collected from cancer treatment centres, pathology laboratories and Oral & Maxillo-Facial (OMF) units throughout the country. In addition, the

2.1.1 Newly registered cancer patients at the cancer treatment centres

In the year 2014, there were 9 government cancer treatment centres involved in data collection (table ii). Relevant data were extracted from cancer patients' clinic records using 'National Cancer Surveillance Form – H 1256'. Data were extracted by the medical officers, nursing officers and development officers attached to the cancer treatment centres, trained pre-intern medical graduates temporarily recruited through WHO Biennium funds and by the cancer registry staff of NCCP.

Category of hospital	Name of the hospital					
National Hospitals	Apeksha Hospital - Maharagama (National Cancer Institute)					
Teaching Hospitals	Kandy, Karapitiya, Anuradhapura, Batticaloa					
Provincial General Hospitals	Badulla, Kurunegala, Rathnapura					
Base Hospital	Tellippalai (Jaffna)					

Table (ii) Distribution of government cancer treatment centres in year 2014

2.1.2 Newly detected cancers at the pathology laboratories

The information on newly detected cancers at the pathology laboratories were received monthly through the 'Cancer Return Form - 1' (H-1290). A total of 45 Histopathology laboratories (13,035 diagnosed patients), 5 Haematology laboratories (258 diagnosed

patients) and one oral pathology laboratory (403 diagnosed patients) have passively sent relevant data for the year 2014 (table ii).

 Table (iii) Distribution of pathology laboratories which sent details of newly diagnosed

 cancer patients in year 2014

Category of	Type of Pathology laboratory									
hospital	Histopathology	Haematology	Oral Pathology							
National	National Hospital of Sri Lanka									
Hospital										
Teaching	De Soysa Hospital for Women, Castle									
Hospitals	Hospital for Women, Lady Ridgeway									
	Hospital, National Eye Hospital,									
	Colombo South, Colombo North,									
	National Hospital for Respiratory									
	Diseases-Welisara, Kandy, Peradeniya,									
	Batticaloa, Jaffna									
Provincial	Kurunegala , Rathnapura, Badulla	Kurunegala								
General		,Badulla								
Hospitals										
District	Avissawella,Gampaha,Negombo,	Kalutara,								
General	Kalutara,Matara,Hambanthota,	Hambanthota,								
Hospitals	Kegalle,Chilaw,	Chilaw								
	Nawalapitiya,Nuwaraeliya, Matale,									
	Monaragala, Vavuniya									
Base Hospital	Homagama,									
	Wathupitiwala,Kethumathi,									
	Horana,Balapitiya,Tangalle,									
	Embilipitiya, Puttlam,									
	Gampola,Dambulla, Karawanella									
University	Faculty of Medicine-Colombo,		Faculty of							
Units	Ruhuna, Jayawardanepura, Ragama		Dental							
			Sciences –							
			Peradeniya							
Other	MRI		-							
Institutions										
Private sector	Gomez Hospital- Avissawella									

2.1.3 Newly diagnosed cancers at the Oral & Maxillo - Facial (OMF) Surgery Units

Data on newly confirmed cancer patients at the Oral & Maxillo-Facial (OMF) surgery units were received annually through the Annual Notification Form of Oral Cancer (H -1294). A total of 15 OMF units have sent relevant data for year 2013 (table iii).

 Table (iv) Distribution of OMF Units which sent details of newly diagnosed cancer

 patients in year 2014

Category of hospital	Name of the hospital
National Hospital	Dental Institute Colombo
Teaching Hospitals	Colombo South, Colombo North, Karapitiya, Kandy
Provincial General Hospitals	Badulla, Kurunegala, Rathnapura
District General Hospitals	Gampaha, Kalutara, Chilaw, Kegalle, Polonnaruwa
Base Hospital	Kuliyapitiya, Panadura
University Units	-

2.1.4 Incorporation of additional cancer incidence data collected for the Population Based Cancer Registry – Colombo district

Two additional data sources were identified for capturing further cancer incidence data from Colombo district when commencing the Population Based Cancer Registry and those data sources were also incorporated as data generating centres for national cancer registry.

Details from Medical Record Departments of Hospitals situated in Colombo district & adjacent districts

The information on cancer patients treated at the secondary and tertiary care hospitals in the government sector, private sector and armed services in the Colombo district and selected hospitals in the adjacent districts were collected through the 'Cancer Return Form -2' (H-1291). A total of 24 Medical Record Departments have sent the details in year 2014 (table iv). Out

 Table (v) Distribution of Medical Record Departments of Hospitals which sent details of

 newly diagnosed cancer patients in year 2014

Category of hospital	Name of the hospital
National Hospital	National Hospital, Dental Institute Colombo, Eye hospital, LRH,DMH,CSHW
Teaching Hospitals	Colombo South, Colombo North, National Hospital for Respiratory Diseases-Welisara, Sri Jayawardanapura
District General Hospitals	Avissawella, Gampaha ,Mulleriyawa
Base Hospital	Panadura, Horana
Private Sector hospitals	Asiri Central, Asiri Medical, Asiri Surgical, Durdans, Lanka, Delmon
Armed Services hospitals	Army hospital, Navy hospital, Police hospital

Details from Divisional Death Registrars of the Colombo district

Details of all cancer related deaths registered by the Divisional Death Registrars of the Colombo district were received through the Cancer Return Form -3. A total of 40 divisional death registrars have sent relevant details for the year 2014.

2.2 Coding of cancer incidence data

According to the instructions of International Classification of Disease for Oncology 3rd edition (ICD-O 3), cancer incidence data were coded according to the site (Topography) and the histology (Morphology) of cancer. The cancer registry staff of the NCCP coded the cancer incidence data.

2.3 Entering of cancer incidence data to the database

Cancer incidence data were entered into the CanReg5 database by the trained data entry operators attached to the NCCP. The process of data entering was closely supervised by the cancer registry staff and was regularly involved in refresher training to the data entry operators to ensure accuracy and quality of data.

2.4 Duplicate checking & verification of data

While entering and confirming the data to the CanReg5 data base, duplicate checking was conducted using 'Person search' option of the CanReg 5 data base. In addition to the duplicate checking done through CanReg 5, further duplicate checking had to be conducted during the data verification stage as well to identify all possible duplicates.

The additional methods used were;

i. Use of Linkpro software

ii. Use of Excel software – Sorted according to the descending or ascending order of selected variables

After removing possible duplicates, consistency checking and verification was conducted using 'IARCcrg' tool & MS Excel.

Mismatches according to;

Age/Incidence and birthdates Age /Site /Histology Site /Histology Sex/Site Sex/Histology Behaviour /Site Behaviour / Histology

Grade /Histology Basis of Diagnosis /Histology were corrected.

After these procedures, preliminary analysis was conducted using CanReg 5 & SPSS to detect further mismatches. Data sources up to the patient clinic files were rechecked in the instances where mismatches were noted by the cancer registry staff of the NCCP. After identifying errors or misclassifications, necessary corrections were done before finalizing the data for analysis.

2.5 Analysis of cancer incidence data

Analysis section of the CanReg 5 package, SPSS and MS Excel software were used to analyze cancer incidence data. The standard cancer registry tables described at the Cancer incidence in 5 continents (CI 5) were generated through CanReg 5 database.

The estimated population data for year 2014 for calculation cancer incidence & mortality data was received from the Department of Census & Statistics.

Table (vi) Estimated population for year 2014

	Estimated Population	
Male	10,059,283	
Female	10,718,312	
Total	20,777,595	

Source – Department of Census & Statistics of Sri Lanka ('000)


Cancer Mortality Data

Cancer mortality data were received through two sources at national level.

(i) Hospital Indoor Morbidity Mortality Return of Medical Statistics unit of Ministry of Health

(ii) Cause specific death data published by the Department of Census & Statistics.

Based on the available data further analysis was conducted.



Cancer Incidence Data of Sri Lanka

Figure 1 : General population in Sri Lanka by 5-year age groups (Population Pyramid)

Table 1 : Population of Sri Lar	1ka: sex distribution 2006 – 2014

Population	ation Year								
('000)	2006	2007	2008	2009	2010	2011	2012	2013	2014
Male	9,889	9,956	10,060	10,148	10,249	10,381	9,856	9,965	10,059
Female	9,969	10,083	10,186	10,302	10,404	10,511	10,502	10,619	10,718
Sex Ratio	99.2	98.7	98.8	98.5	98.5	98.8	93.8	93.8	93.9

	a		0 /		
Year	Sex	Number	%	CR	ASR
	Male	6,205	44.1	62.7	69.2
2006	Female	7,875	55.9	79	79.5
	Total	14,080		70.9	74.2
	Male	6,356	46.6	63.8	70.9
2007	Female	7,279	53.4	72.2	72.8
	Total	13,635		68	71.6
	Male	7,695	46.6	76.5	85.5
2008	Female	8,816	53.4	86.6	88
	Total	16,511		81.6	86.4
	Male	7,858	46.5	77.4	86.4
2009	Female	9,030	53.5	87.7	89.1
	Total	16,888		82.6	87.5
	Male	7,993	47.1	78.0	87.4
2010	Female	8,970	52.9	86.2	87.7
	Total	16,963		82.1	87.3
	Male	8,370	47.9	80.6	90.4
2011	Female	9,112	52.1	86.7	88.7
	Total	17,482		83.7	89.2
	Male	11,363	49.2	114.9	106.9
2012	Female	11,773	50.8	111.7	94.9
	Total	23,136		113.3	99.7
	Male	11,364	48.3	114.0	106.3
2013	Female	12,167	51.7	114.6	97.4
	Total	23,531		114.3	100.7
	Male	12,021	47.6	119.5	112.0
2014	Female	13,250	52.4	123.6	105.3
	Total	25,271		121.6	107.3

Table 2: Cancer Incidence by sex, 2006-2014




Figure 2: Crude Incidence Rates-Sri Lanka, 2006 – 2014






Figure 3 : Age standardized Incidence Rates- Sri Lanka, 2006 - 2014








Figure 5: Age Specific Cancer Incidence rates inSri lanka -2014

Age		Male			Female			Total	
Group	Cases	Populati- on	Incidence	Cases	Populati- on	Incidence	Cases	Populati- on	Incidence
Unknown	29			25			54		
00-04	117	897,764	13.03	113	882,883	12.80	230	1,780,647	12.92
05-09	97	900,547	10.77	51	883,758	5.77	148	1,784,305	8.29
10-14	76	846,301	8.98	67	827,888	8.09	143	1,674,189	8.54
15-19	96	836,858	11.47	122	841,462	14.50	218	1,678,320	12.99
20-24	116	757,437	15.31	149	806,744	18.47	265	1,564,181	16.94
25-29	118	758,756	15.55	250	826,029	30.27	368	1,584,785	23.22
30-34	226	813,215	27.79	452	859,885	52.57	678	1,673,100	40.52
35-39	263	700,066	37.57	625	737,812	84.71	888	1,437,879	61.76
40-44	465	675,118	68.88	936	711,789	131.50	1401	1,386,907	101.02
45-49	787	630,823	124.76	1237	681,334	181.56	2024	1,312,157	154.25
50-54	1289	593,220	217.29	1723	651,175	264.60	3012	1,244,395	242.05
55-59	1575	511,115	308.15	1696	574,776	295.07	3271	1,085,891	301.23
60-64	1914	434,043	440.97	1855	502,365	369.25	3769	936,408	402.50
65-69	1823	289,438	629.84	1509	356,449	423.34	3332	645,887	515.88
70-74	1490	185,482	803.31	1209	235,116	514.21	2699	420,598	641.71
75+	1540	229,100	672.20	1231	338,847	363.29	2771	567,947	487.90
Total	12021	10,059,283	119.50	13250	10,718,312	123.62	25271	20,777,595	121.63

Table 3Cancer incidence by 5 year age groups & sex - 2014

	Male					Fema	ale		
ICD 10 code	Site	No	CR	ASR	ICD 10	Site	No	CR	ASR
C00-C06	Lip, tongue and mouth	1923	19.1	17.6	C50	Breast	3291	30.7	26.0
C33-C34	Trachea, bronchus and lung	1156	11.5	10.7	C73	Thyroid	1432	13.4	11.8
C15	Oesophagus	903	9.0	8.3	C53	Cervix uteri	1090	10.2	8.5
C18-C20	Colon and rectum	800	8.0	7.4	C18-C20	Colon and rectum	965	9.0	7.5
C61	Prostate	791	7.9	7.5	C56	Ovary	951	8.9	7.6
C09-C14	Pharynx	699	6.9	6.4	C15	Oesophagus	712	6.6	5.4
C81-C85 and C96	Lymphoma	583	5.8	5.5	C54-C55	Uterus	660	6.2	5.1
C32	Larynx	571	5.7	5.3	C00-C06	Lip, tongue and mouth	529	4.9	4.1
C91-C95	Leukaemia	466	4.6	4.6	C81-C85 and C96	Lymphoma	405	3.8	3.4
C67	Bladder	442	4.4	4.1	C33-C34	Trachea, bronchus and lung	325	3.0	2.5
Total		12,021	119.5	112.0	Total		13,250	123.6	105.3

Table 4 : Leading cancer sites by sex - 2014




Figure 6 - Proportion of leading cancers in Males in Sri Lanka – 2014




Figure 7 - Proportion of leading cancers in Females in Sri Lanka – 2014

									Ag	e Grou	ıp								
IC	D 10 code and site	Unk now n	00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	Total
C00	Lip	1	0	0	0	0	0	0	0	2	6	4	13	9	11	8	9	7	70
C01	Base of tongue	0	0	0	0	0	0	0	1	3	12	23	28	35	38	21	11	20	192
C02	Unspecified part of tongue	0	0	0	0	0	1	1	6	13	31	60	78	71	63	62	40	34	460
C03	Gum	0	0	0	0	0	0	0	0	0	7	9	19	21	21	19	14	20	130
C04	Floor of mouth	0	0	0	0	0	0	0	1	0	3	11	22	23	19	21	7	9	116
C05	Palate	0	0	1	0	0	0	1	4	7	12	9	28	43	33	25	26	22	211
C06	Other and unspecified parts of mouth	1	0	0	1	0	0	2	4	5	36	65	75	10 1	11 8	12 0	96	12 0	744
C07	Parotid gland	1	0	0	6	2	2	1	5	7	5	3	9	10	5	11	7	11	85
C08	Other and unspecified major salivary gland	0	0	0	1	0	0	0	3	0	4	2	4	1	3	1	2	2	23
C09	Tonsil	0	0	0	0	0	1	0	0	0	10	20	46	22	28	20	17	18	182
C10	Oropharynx	0	0	0	0	0	0	1	0	5	8	11	20	29	15	20	19	4	132
C11	Nasopharynx	0	0	0	0	0	1	1	0	0	1	3	7	3	3	7	8	2	36
C12	Pyriform sinus	0	0	0	0	0	0	0	0	3	6	14	30	34	42	24	28	30	211
C13	Hypopharynx	0	0	0	0	0	0	0	0	0	5	5	6	8	10	9	7	10	60
C14	Ill-defined sites of lip, oral cavity and pharynx	0	0	0	0	0	0	0	0	0	3	7	10	19	10	8	7	14	78
C15	Oesophagus	3	0	0	0	0	0	0	5	9	19	55	10 3	14 7	14 7	16 0	13 2	12 3	903
C16	Stomach	2	0	0	0	0	1	0	1	6	6	20	52	66	63	68	62	38	385
C17	Small intestine	0	0	0	0	0	0	0	0	2	0	3	5	4	11	6	3	6	40
C18	Colon	0	0	0	1	3	1	4	9	10	16	25	39	40	60	53	50	45	356
C19	Rectosigmoid junction	0	0	0	0	0	0	0	0	4	5	3	4	9	12	15	11	9	72
C20	Rectum	2	0	0	0	0	1	3	9	6	14	17	23	51	68	55	61	62	372
C21	Anus	0	0	0	0	0	0	0	0	1	2	1	7	5	8	10	13	13	60
C22	Liver	4	7	1	0	1	0	0	3	2	1	12	24	27	44	44	45	32	247
C23	Gallbladder	0	0	0	0	0	0	0	1	1	0	3	2	5	1	3	5	1	22

Table 05: Cancer cases by age group – Male 2014

									Ag	e Grou	ıp								
IC	D 10 code and site	Unk now n	00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	62-69	70-74	75+	Total
C24	Other and unspecified parts of billiary tract	0	0	0	0	0	0	1	1	0	1	6	9	8	11	9	4	4	54
C25	Pancreas	0	0	0	0	0	1	1	1	1	3	7	17	7	22	10	8	8	86
C26	Other and ill- defined digestive organs	0	0	0	0	0	0	0	0	1	0	1	2	0	3	3	2	5	17
C30	Nasal cavity and middle ear	0	1	1	0	1	1	1	0	1	1	2	4	3	4	8	9	0	37
C31	Accessory sinuses	0	1	0	0	0	0	0	0	3	3	3	6	4	7	10	3	5	45
C32	Larynx	0	0	0	0	0	1	0	5	7	7	35	67	90	12 1	92	82	64	571
C33	Trachea	0	0	0	0	0	0	0	0	0	0	2	0	0	2	0	0	0	4
C34	Bronchus and lung	3	0	0	0	0	2	5	4	11	28	57	11 6	18 7	23 7	23 6	14 5	12 1	1152
C37	Thymus	0	0	0	0	0	1	0	2	1	1	2	2	3	2	4	1	0	19
C38	Heart, mediastinum and pleura	0	1	1	2	1	0	2	4	0	0	0	1	2	0	0	0	1	15
C40	Bone and articular cartilage of limbs	0	1	3	12	8	2	2	6	1	1	1	3	0	2	0	0	2	44
C41	Bone and articular cartilage of other and unspecified sites	0	1	1	6	4	7	1	1	0	2	3	0	3	4	4	2	2	41
C43	Malignant melanoma of skin	0	0	0	1	1	0	0	2	3	0	7	3	6	9	8	5	9	54
C44	Skin	0	1	1	0	0	3	3	4	11	12	20	28	35	45	27	30	37	257
C45	Mesothelioma	0	0	0	0	0	0	0	0	1	0	0	2	0	1	1	0	1	6
C46	Kaposi sarcoma	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	1
C47	Peripheral nerves and autonomic nervous system	0	2	0	1	0	1	0	1	0	1	0	3	0	1	0	0	0	10
C48	Retroperitoneum and peritoneum	0	0	1	0	0	0	0	2	0	0	1	2	1	1	1	2	3	14
C49	Connective and soft tissue	0	0	3	2	5	3	4	10	5	8	10	11	12	9	6	11	8	107
C50	Breast	1	0	0	0	0	0	1	0	3	6	5	8	8	9	8	10	10	69

									Ag	e Grou	ıp								
IC	D 10 code and site	Unk now n	00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	62-69	70-74	75+	Total
C60	Penis	0	0	0	0	0	0	0	3	2	8	8	13	14	14	12	9	14	97
C61	Prostate	2	0	0	0	0	0	0	1	2	1	4	20	56	11 3	16 6	17 6	25 0	791
C62	Testis	0	8	2	0	2	4	10	7	4	5	1	2	2	5	1	0	1	54
C63	Other and unspecified male genital organs	0	0	0	0	0	0	0	0	0	0	1	1	1	2	2	3	1	11
C64	Kidney	0	8	1	1	1	0	2	6	13	12	12	25	31	37	29	23	16	217
C65	Renal pelvis	0	0	0	0	0	0	0	0	0	0	0	2	0	1	1	0	0	4
C66	Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1
C67	Bladder	1	0	0	0	0	1	2	1	8	10	21	38	59	79	80	65	77	442
C68	Other and unspecified urinary organs	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	2	4
C69	Eye and adnexa	0	13	2	0	0	0	0	2	1	0	1	0	0	1	0	0	3	23
C70	Meninges	0	0	0	0	0	1	0	2	0	0	1	1	0	3	2	0	0	10
C71	Brain	1	9	16	8	3	4	5	16	14	23	14	23	17	19	11	11	7	201
C72	Other parts of central nervous system	0	0	0	0	1	0	0	1	0	1	0	1	0	1	0	1	0	6
C73	Thyroid	0	0	0	1	10	22	19	33	36	32	29	27	28	26	16	15	16	310
C74	Adrenal gland	0	3	3	1	0	1	1	0	0	0	0	0	1	2	2	0	0	14
C75	Other endocrine gland and related structure	0	0	0	1	1	1	0	0	0	0	0	0	0	1	0	0	0	4
C76	Other and ill- defined site	1	2	2	0	1	0	0	1	1	3	6	10	7	4	8	9	6	61
C80	Unknown primary	4	0	1	1	3	2	9	5	6	28	51	83	95	11 8	12 2	85	88	701
C81	Hodgkin disease	0	2	2	1	3	17	7	9	4	10	6	11	2	11	6	5	8	104
C82	Follicular(nodular) non-Hodgkin lymphoma	0	0	0	0	1	0	1	2	1	5	3	7	2	8	6	9	1	46
C83	Diffuse non- Hodhkin lymphoma	0	6	6	5	2	1	1	7	3	5	5	11	10	17	13	4	16	112

									Ag	e Grou	ıp								
IC	D 10 code and site	Unk now n	00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	Total
C84	Peripheral and cutaneous T-cell lymphoma	0	0	1	1	3	2	1	0	1	2	2	4	2	3	1	2	2	27
C85	Other and unspecified types of non-Hodgkin lymphoma	2	0	0	2	5	10	6	3	12	9	26	23	31	48	41	29	37	284
C88	Immunoproliferati ve disease	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	1	3
C90	Multiple myeloma	0	0	0	0	0	0	0	2	1	1	14	25	32	36	40	30	26	207
C91	Lymphoid leukaemia	0	37	41	14	20	7	7	13	4	10	7	6	8	7	13	3	9	206
C92	Myeloid leukaemia	0	3	4	5	9	12	10	12	14	13	24	17	20	23	25	11	23	225
C93	Monocytic leukaemia	0	3	1	0	2	0	0	0	0	1	0	0	0	1	2	1	1	12
C94	Other leukaemias of specified cell type	0	1	0	0	1	0	0	0	0	0	1	1	2	1	0	0	0	7
C95	Leukaemia of unspecified cell type	0	0	0	1	2	1	1	4	0	0	1	0	1	0	5	0	0	16
C96	Other and unspecified lymphoid, haematopoietic and related tissue	0	6	2	1	0	0	1	0	0	0	0	0	0	0	0	0	0	10
D45 and D47	Myeloproliferative disorders	0	0	0	0	0	0	0	0	0	0	0	0	1	2	0	1	0	4
C46	Myelodysplastic syndrome	0	1	0	0	0	0	0	1	0	0	1	0	1	5	1	4	3	17
	Total	29	117	76	76	96	116	118	226	263	465	787	1289	1575	1914	1823	1490	1540	12021

									Aş	ge Grou	ւթ								Tot
IC	D 10 code and site	Unkn own	00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	al
C 00	Lip	0	0	0	0	0	0	0	0	0	0	1	1	3	5	1	0	3	14
C 01	Base of tongue	0	0	0	0	0	0	0	2	0	1	0	3	2	0	2	3	7	20
C 02	Unspecified part of tongue	0	0	0	0	0	0	1	2	5	4	11	18	14	21	14	10	18	118
C 03	Gum	0	0	0	0	0	0	0	0	1	0	1	8	7	7	13	8	11	56
C 04	Floor of mouth	0	0	0	0	0	0	0	0	0	2	1	1	3	3	3	1	4	18
C 05	Palate	0	0	0	0	2	1	0	3	1	5	6	6	5	8	6	6	7	56
C 06	Other and unspecified parts of mouth	0	0	0	0	0	1	2	0	2	7	15	24	33	28	46	42	47	247
C 07	Parotid gland	0	1	0	0	0	2	2	4	3	5	5	4	5	5	2	3	3	44
C 08	Other and unspecified major salivary gland	0	0	0	0	0	0	0	1	0	0	0	3	2	3	3	2	0	14
C 09	Tonsil	0	0	0	0	0	0	0	1	0	2	0	2	2	2	2	2	1	14
C 10	Oropharynx	0	0	0	0	0	0	0	0	0	0	1	2	2	1	3	6	1	16
C 11	Nasopharynx	0	0	0	0	1	3	2	0	0	0	2	0	0	3	0	0	0	11
C 12	Pyriform sinus	0	0	0	0	0	0	0	0	0	0	3	4	5	8	6	7	4	37
C 13	Hypopharyn x	0	0	0	0	0	0	0	0	0	1	1	3	3	10	9	3	5	35
C 14	Ill-defined sites of lip, oral cavity and pharynx	0	0	0	0	0	0	0	0	0	0	2	3	1	4	2	6	4	22
C 15	Oesophagus	2	0	0	0	1	1	0	2	6	11	35	70	80	132	115	110	147	712
C 16	Stomach	0	0	0	1	1	2	1	0	4	10	7	30	30	27	44	29	33	219

Table 06: Cancer cases by age group – Female 2014

									Ag	ge Grou	р								Tot
IC	D 10 code and site	Unkn own	00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	al
C 17	Small intestine	0	0	0	1	0	0	0	1	0	1	4	5	13	5	4	5	1	40
C 18	Colon	2	0	0	1	6	0	7	12	18	29	35	49	69	66	55	55	67	471
C 19	Rectosigmoi d junction	0	0	0	0	0	0	1	1	4	3	3	12	10	13	14	5	6	72
C 20	Rectum	0	0	0	0	0	0	2	11	14	24	36	45	65	64	63	45	53	422
C 21	Anus	0	0	0	0	0	0	0	0	0	1	0	3	6	6	9	8	6	39
C 22	Liver	1	3	2	0	0	0	0	3	1	2	0	9	8	14	16	18	10	87
C 23	Gallbladder	0	0	0	0	0	0	0	0	4	1	1	7	5	7	5	5	5	40
C 24	Other and unspecified parts of billiary tract	0	0	0	0	0	0	0	1	1	2	4	11	6	10	5	9	2	51
C 25	Pancreas	1	0	0	0	0	1	0	0	4	5	7	3	10	12	13	7	10	73
C 26	Other and ill-defined digestive organs	0	0	0	0	0	0	0	0	1	0	0	2	2	0	3	1	5	14
C 30	Nasal cavity and middle ear	0	1	0	0	0	0	0	1	2	1	2	2	2	3	0	1	0	15
C 31	Accessory sinuses	0	0	0	0	0	0	0	1	0	1	1	1	2	6	0	2	2	16
C 32	Larynx	0	0	1	0	0	0	0	0	2	1	1	7	7	11	13	6	2	51
C 33	Trachea	0	0	0	0	0	0	1	0	0	0	0	0	2	2	0	1	0	6
C 34	Bronchus and lung	1	1	0	0	0	3	2	4	16	16	26	35	44	62	39	37	33	319
C 37	Thymus	0	0	0	0	0	0	0	0	0	1	3	0	3	0	1	0	1	9
C 38	Heart, mediastinum and pleura	0	1	0	0	0	0	1	0	0	1	1	1	1	4	0	0	1	11
C 40	Bone and articular cartilage of	0	0	3	9	10	1	2	2	0	1	1	4	1	2	0	2	0	38

									A	ge Grou	р								Tot
IC	D 10 code and site	Unkn own	00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	al
	limbs																		
C 41	Bone and articular cartilage of other and unspecified sites	0	1	0	2	3	0	2	1	1	1	1	2	1	3	2	1	2	23
C 43	Malignant melanoma of skin	0	0	0	0	0	1	1	1	0	0	2	5	4	6	6	6	11	43
C 44	Skin	1	0	0	0	3	0	1	0	2	3	12	30	19	26	23	29	43	192
C 45	Mesotheliom a	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	1	0	3
C 47	Peripheral nerves and autonomic nervous system	0	3	0	1	1	0	0	0	1	0	2	4	0	0	0	1	0	13
C 48	Retroperiton eum and peritoneum	0	1	0	0	0	1	0	2	1	0	6	9	1	10	4	6	0	41
C 49	Connective and soft tissue	1	8	5	1	2	4	4	4	8	11	10	7	11	12	8	4	6	106
C 50	Breast	6	0	0	0	0	10	28	84	183	325	443	506	494	445	343	225	199	329 1
C 51	Vulva	0	0	0	0	0	0	2	2	0	2	1	3	8	4	4	2	16	44
C 52	Vagina	0	1	0	0	1	0	0	0	2	0	4	6	7	8	9	6	18	62
C 53	Cervix uteri	0	0	0	0	0	0	4	8	35	66	128	168	165	170	134	98	114	109 0
C 54	Corpus uteri	0	0	0	0	0	0	1	11	7	16	21	75	123	124	94	60	30	562
C 55	Uterus unspecified	0	0	0	0	0	0	0	1	0	8	9	19	10	18	17	9	7	98
C 56	Ovary	0	2	2	5	12	20	19	33	28	69	96	161	154	129	96	71	54	951
C 57	Other and unspecified female genital organs	1	0	0	0	0	0	0	0	0	2	5	9	5	3	2	2	1	30

									Ag	ge Grou	p								Tot
IC	D 10 code and site	Unkn own	00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	al
C 58	Placenta	0	0	0	0	0	1	2	3	1	1	1	1	0	0	0	0	0	10
C 64	Kidney	0	12	2	0	1	0	0	1	2	6	4	8	10	8	7	10	7	78
C 65	Renal pelvis	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	2
C 66	Ureter	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	2	4
C 67	Bladder	0	1	0	0	0	0	2	0	1	4	5	7	13	17	19	15	24	108
C 69	Eye and adnexa	0	18	1	0	0	0	0	0	0	0	1	1	3	2	1	1	1	29
C 70	Meninges	0	1	0	0	1	0	0	3	0	6	6	1	3	4	2	1	1	29
C 71	Brain	0	4	10	10	5	6	4	12	5	7	10	12	14	11	4	8	3	125
C 72	Other parts of central nervous system	0	0	1	2	1	1	0	0	0	0	0	0	0	0	0	0	2	7
C 73	Thyroid	5	0	2	10	39	63	118	198	209	203	139	150	73	84	50	55	34	143 2
C 74	Adrenal gland	0	9	0	0	0	0	0	0	0	0	2	1	1	1	0	0	1	15
C 75	Other endocrine gland and related structure	0	0	1	0	0	0	0	0	0	0	0	1	0	1	0	0	0	3
C 76	Other and ill-defined site	1	3	1	0	0	0	1	1	2	5	2	4	2	4	1	4	7	38
C 80	Unknown primary	3	1	1	0	1	0	1	11	10	19	33	60	47	83	69	57	57	453
C 81	Hodgkin disease	0	0	0	2	8	13	10	4	6	3	4	5	5	5	3	1	5	74
C 82	Follicular(no dular) non- Hodgkin lymphoma	0	0	0	0	0	0	1	0	0	3	0	4	0	4	4	3	1	20
C 83	Diffuse non- Hodhkin lymphoma	0	2	1	2	2	2	1	0	2	3	13	4	7	10	9	9	7	74

									Aş	ge Grou	ıp								Tot
IC	D 10 code and site	Unkn own	00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	al
C 84	Peripheral and cutaneous T- cell lymphoma	0	0	0	0	2	0	2	2	1	2	3	1	2	2	0	2	3	22
C 85	Other and unspecified types of non- Hodgkin lymphoma	0	0	1	0	5	5	13	2	9	8	23	18	11	36	31	25	22	209
C 88	Immunoproli ferative disease	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	2
C 90	Multiple myeloma	0	0	0	0	0	0	0	0	1	4	12	29	27	36	28	26	22	185
C 91	Lymphoid leukaemia	0	29	16	15	5	2	0	2	2	8	2	7	4	7	4	5	8	116
C 92	Myeloid leukaemia	0	5	1	3	6	5	8	12	14	11	20	19	14	19	16	15	16	184
C 93	Monocytic leukaemia	0	0	0	0	1	0	0	0	1	1	0	1	0	0	0	1	1	6
C 94	Other leukaemias of specified cell type	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	2	0	4
C 95	Leukaemia of unspecified cell type	0	1	0	0	1	0	0	0	0	1	0	1	2	1	1	0	0	8
C 96	Other and unspecified lymphoid, haematopoie tic and related tissue	0	4	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	6
D 45 an d D 47	Myeloprolife rative disorders	0	0	0	0	0	0	0	0	1	0	0	2	0	2	0	0	1	6
C 46	Myelodyspla stic syndrome	0	0	0	1	0	0	0	2	0	0	1	2	1	4	5	3	6	25
Tota	1	25	113	51	67	122	149	250	452	625	936	1237	1723	1696	1855	1509	1209	1231	13250

									anka Ca by age											
SITE	ALL A		0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75+	(%)	ICD (10th)
Lip Tongue Mouth Salivary glands Tonsil Other oropharynx Nasopharynx Hypopharynx Pharynx unspecified	70 652 1201 108 182 132 36 271 78	1 0 1 0 0 0 0 0 0	-	1	- 1 7 - - -	2	1 2 1 - -	1 3 1 - 1 1 -	798	2 16 12 7 5 3	6 43 58 9 10 8 1 11 3	4 83 94 5 20 11 3 19 7	$ \begin{array}{r} 13 \\ 106 \\ 144 \\ 13 \\ 46 \\ 20 \\ 7 \\ 36 \\ 10 \\ \end{array} $	9 106 188 11 22 29 3 42 19	11 101 191 8 28 15 3 52 10	8 83 185 12 20 20 7 33 8	9 51 143 9 17 19 8 35 7	7 54 171 13 18 4 2 40 14	0.6 5.5 10.2 0.9 1.5 1.1 0.3 2.3 0.7	C00 C01-02 C03-06 C07-08 C09 C10 C11 C12-13 C14
Oesophagus Stomach Small intestine Colon Rectum Anus Liver Gallbladder etc. Pancreas	903 385 40 356 444 60 247 76 86	3 0 0 2 0 4 0 0	7		1	3	1 - 1 - - - 1	- 4 3 - 1 1	5 1 9 9 - 3 2 1	9 6 2 10 10 1 2 1 1	19 6 16 19 2 1 1 3	55 20 3 25 20 1 12 9 7	103 52 5 39 27 7 24 11 17	147 66 4 60 5 27 13 7	147 63 11 60 80 8 44 12 22	160 68 53 70 10 44 12 10	132 62 3 50 72 13 45 9 8	123 38 6 45 71 13 32 5 8	7.7 3.3 0.3 3.0 3.8 0.5 2.1 0.6 0.7	C15 C16 C17 C18 C19-20 C21 C22 C23-24 C25
Nose, sinuses etc. Larynx Trachea, bronchus and lung Other thoracic organs	82 571 1156 34	0 0 3 0	2	1	2	1	1 2 1	1 5 2	5 4 6	4 7 11 1	4 7 28 1	5 35 59 2	10 67 116 3	7 90 187 5	11 121 239 2	18 92 236 4	12 82 145 1	5 64 121 1	0.7 4.9 9.8 0.3	C30-31 C32 C33-34 C37-38
Bone Melanoma of skin Other skin	85 54 257	0 0 0	2	4	18	12	- 3	3	7 2 4	3	3 12	4 7 20	3 3 28	3 6 35	6 9 45	4 8 27	2 5 30	4 9 37	0.7 0.5 2.2	C40-41 C43 C44
Mesothelioma Kaposi sarcoma Connective and soft tissue	6 1 117	0 0 0	2	3	-3	5	4	4	: 11	1 1 5	- - 9	-	2	-	1	1 - 6	: 11	1	0.1 0.0 1.0	C45 C46 C47,C49
Breast Penis Prostate Testis Other male genital organs	69 97 791 54 11	1 0 2 0 0	- 8	2	-	2	4	1	3 1 7	3 2 2 4	6 8 1 5	5 8 4 1	8 13 20 2 1	8 14 56 2	9 14 113 5 2	8 12 166 1 2	10 9 176 - 3	10 14 250 1	0.6 0.8 6.7 0.5 0.1	C50 C60 C61 C62 C63
Kidney Renal pelvis Ureter Bladder Other urinary organs	217 4 1 442 4	0 0 0 1	8	1	1	1		2	6 - 1	13 - 8	12 - 10	12	25 2 38	31 59	37 1 1 79	29 1 - 80 1	23 - 65	16 - 77 2	1.8 0.0 0.0 3.8 0.0	C64 C65 C66 C67 C68
Eye Brain, nervous system Thyroid Adrenal gland Other endocrine	23 217 310 14 4	0 1 0 0 0	13 9 - 3	2 16 3	8 1 1 1	4 10 -	5 22 1 1	5 19 1	2 19 33	1 14 36	24 32	1 15 29	25 27	17 28 1	1 23 26 2 1	13 16 2	12 15	3 7 16	0.2 1.8 2.6 0.1 0.0	C69 C70-72 C73 C74 C75
Hodgkin disease Non-Hodgkin lymphoma Immunoproliferative diseases Multiple myeloma	104 479 3 207	0 2 0 0	2 12 -	2 9 -	1 9 -	3 11 -	17 13	7 10 -	9 12 - 2	4 17 - 1	10 21 1	6 36 1 14	11 45 - 25	2 45 32	11 76 1 36	6 61 - 40	5 44 - 30	8 56 1 26	0.9 4.1 0.0 1.8	C81 C82-85,C96 C88 C90
Lymphoid leukaemia Myeloid leukaemia Leukaemia unspecified Myeloproliferative disorders Myelodysplastic syndromes	206 244 16 4 17	0 0 0 0	37 7 - 1	41 5 - -	14 5 1 -	20 12 2	7 12 1 -	7 10 1 -	13 12 4 - 1	4 14 - -	10 14 - -	7 25 1 - 1	6 18 - -	8 22 1 1 1	7 25 - 2 5	13 27 5 -	3 12 - - - 4	9 24 - - 3	1.8 2.1 0.1 0.0 0.1	C91 C92-94 C95 MPD MDS
Other and unspecified	793	5	2	4	1	4	2		8	8	31	59	97	103	126	134	98	102	6.7	O&U
All sites All sites but C44	12021 11764	29 29	117	97 96	76 76	96 96	116	118 115	226 222	263 252	465 453	787 767	1289 1261	1575 1540	1914 1869	1823 1796	1490 1460	1540 1503	100.0	ALL ALLbC44

Table 7 Number of incidence cancers by five-year age group and site among Males in Sri Lanka, 2014

									e		-										
									Sri L Cases t	anka Ca											
									Cases t	y age g	roup (P	erioa) -	remale								
SITE	ALL A AGES U			0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75+	(%)	ICD (10th)
Lip Tongue Mouth Salivary glands Tonsil Other oropharynx Nasopharynx Hypopharynx Pharynx unspecified Ocsophagus	14 138 377 58 14 16 11 72 22 712	0 0 0 0 0 0 0 0 0 0 2		1		-	2	2 2 3	1 2 2 2	4 3 5 1 - -	5 4 3	5 14 5 2 - - 1 -	$ \begin{array}{c} 1 \\ 23 \\ 5 \\ - \\ 1 \\ 2 \\ 4 \\ 2 \\ 35 \\ \end{array} $	1 39 7 2 2 - 7 3 71	3 16 48 7 2 2 2 - 8 1 80	5 21 46 8 2 1 3 18 4 133	1 68 5 2 3 - 15 2 115	13 57 5 2 6 - 10 6 110	3 25 69 3 1 1 - 9 4 147	0.1 1.1 2.9 0.4 0.1 0.1 0.1 0.6 0.2 5.5	C00 C01-02 C03-06 C07-08 C09 C10 C11 C12-13 C14 C15
Stomach Stomach Colon Rectum Anus Liver Gallbladder etc. Pancreas	219 40 471 494 39 87 91 73	0 0 2 0 1 0 1		3	2	1	1	2	1 7 3	1 12 12 3 1	4 	10 1 29 27 1 2 3 5	7 4 35 39 - 5 7	30 5 49 57 3 9 18 3	30 13 69 75 6 8 11 10	27 5 66 77 6 14 17 12	44 4 55 77 9 16 10 13	29 5 55 50 8 18 14 7	33 1 67 59 6 10 7 10	1.7 0.3 3.6 3.8 0.3 0.7 0.7 0.6	C16 C17 C18 C19-20 C21 C22 C23-24 C25
Nose, sinuses etc. Larynx Trachea, bronchus and lung Other thoracic organs Bone	31 51 325 20 61	0 0 1 0		1 - 1 1	1		13	3	3 1 4	2 4	2 2 16 -	2 1 16 2 2	3 1 26 4 2	3 7 35 1 6	4 7 46 4 2	9 11 64 4 5	13 39 1 2	3 6 38 - 3	2 2 33 2 2	0.2 0.4 2.5 0.2 0.5	C30-31 C32 C33-34 C37-38 C40-41
Melanoma of skin Other skin	43 192	0 / 0		2	1	1	3	-	1 1	-	2	3	12	5 30	19	26	6 23	6 29	11 43	0.3 1.5	C43 C44
Mesothelioma Kaposi sarcoma Connective and soft tissue	3 0 119	0		- 11	5	2	- 3	4	4	4	- 9	iii	12	11	i	12	- 8	5	6	0.0 0.0 0.9	C45 C46 C47,C49
Breast	3291	6		-	-	-	-	10	28	84	183	325	443	506	494	445	343	225	199	25.2	C50
Vulva Vagina Cervix uteri Corpus uteri Uterus unspecified Ovary Other female genital organs Placenta	44 62 1090 562 98 <i>951</i> 30 10	0 0 0 0 0 1		1	2		1 - - - - - - - - - - - - - - - - - - -	20	2 4 1 19 2	2 8 11 1 33 - 3	2 35 7 28	2 66 16 8 69 2 1	1 4 128 21 9 96 5 1	3 168 75 19 <i>161</i> 9	8 7 165 123 10 <i>154</i> 5	4 8 170 124 18 <i>129</i> 3	4 9 134 94 17 96 2	2 6 98 60 9 71 2	16 18 114 30 7 54 1	0.3 0.5 8.3 4.3 0.8 7.3 0.2 0.1	C51 C52 C53 C54 C55 C56 C57 C58
Kidney Renal pelvis Ureter Bladder Other urinary organs	78 2 4 108 0	0 0 0 0		12	2	-	1	-	2	1	2 1 1	6 - - 4	4 - 5 -	8 1 7	10 1 13	8 - 1 17 -	7 - 19 -	10 - 15 -	7 - 2 24 -	0.6 0.0 0.0 <i>0.8</i> 0.0	C64 C65 C66 C67 C68
Eye Brain, nervous system Thyroid Adrenal gland Other endocrine	29 161 1432 15 3	0 0 5 0 0		18 5 - 9 -	1 11 2 - 1	12	7 39	7 63	4 118	15 198	5 209	13 203	1 16 139 2	1 13 150 1 1	3 17 73 1	2 15 84 1 1	1 6 50 -	1 9 55	1 6 34 1	0.2 1.2 11.0 0.1 0.0	C69 C70-72 C73 C74 C75
Hodgkin disease Non-Hodgkin lymphoma Immunoproliferative diseases Multiple myeloma	74 331 2 185	0 0 0		6	2	23	8 10 -	13 7 -	10 17 -	4	6 12 1	3 16 - 4	4 39 12	5 27 29	5 20 27	5 52 36	3 44 2 28	1 39 26	5 33 22	0.6 2.5 0.0 1.4	C81 C82-85,C96 C88 C90
Lymphoid leukaemia Myeloid leukaemia Leukaemia unspecified Myeloproliferative disorders Myelodysplastic syndromes	116 194 8 6 25	0 0 0 0		29 5 1 -	16 1 - -	15 3 - - 1	5 7 1 -	25	9	2 12 - 2	2 15 1	8 12 1 -	2 20 - - 1	7 21 1 2 2	4 14 2 - 1	7 19 1 2 4	4 16 1 - 5	5 18 - - 3	8 17 - 1 6	0.9 1.5 0.1 0.0 0.2	C91 C92-94 C95 MPD MDS
Other and unspecified	546	4		5	2	-	1	1	2	14	14	24	41	75	52	97	77	68	69	4.2	O & U
All sites	13250	25		13	51	66	121	148	250	453	625	936	1237	1724	1696	1856	1509	1209	1231	100.0	ALL
All sites but C44	13058	24	1	13	51	66	118	148	249 Table	453 builtWed	623 Mar 03	933 14:14:2	1225 1 IST 20	1694 21 by Ca	1677 inReg5.	1830	1486	1180	1188	100.0	ALLbC44

Table 8 Number of incidence cancers by five-year age group and site among Females in Sri Lanka,2014

							Incide			ancer R) by age			- Male												
SITE	ALL /		()- :	- 10	- 15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75+	CRUI RA'				CUM 0-74	ASR	ICD (10th)
Lip Tongue Mouth Salivary glands Tonsil Other oropharynx Nasopharynx Hypopharynx Pharynx unspecified	70 652 1201 108 182 132 36 271 78	1 0 1 1 0 0 0 0 0	-	0.	- 1 0. - - - -		0.1	0.1 0.4 0.1 0.1 0.1	0.9 1.1 1.0 - - -	0.3 2.3 1.7 1.0 0.7 0.4	0.9 6.4 8.6 1.3 1.5 1.2 0.1 1.6 0.4	0.6 13.2 14.9 0.8 3.2 1.7 0.5 3.0 1.1	2.2 17.9 24.3 2.2 7.8 3.4 1.2 6.1 1.7	1.8 20.7 36.8 2.2 4.3 5.7 0.6 8.2 3.7	2.5 23.3 44.0 1.8 6.5 3.5 0.7 12.0 2.3	2.8 28.7 63.9 4.1 6.9 6.9 2.4 11.4 2.8	4.9 27.5 77.1 4.9 9.2 10.2 4.3 18.9 3.8	3.1 23.6 74.6 5.7 7.9 1.7 0.9 17.5 6.1	1	5.5 1.9 1 1.1 1.8 1.3 0.4 2.7 0.8	5.5 10.2 0.9 1.5 1.1 0.3 2.3 0.7	0.04 0.42 0.66 0.06 0.12 0.08 0.02 0.16 0.05	0.08 0.70 1.37 0.10 0.20 0.17 0.05 0.31 0.08	0.6 5.9 11.0 1.7 1.2 0.3 2.5 0.7	C00 C01-02 C03-06 C07-08 C09 C10 C11 C12-13 C14
Oesophagus Stomach Small intestine Colon Rectum Anus Liver Gallbladder etc. Pancreas	903 385 40 356 444 60 247 76 86	3 0 0 2 0 4 0 0	0	8 0.		0.4	0.1 0.1 0.1	0.5 0.4 0.1 0.1	0.6 0.1 1.1 1.1 0.4 0.2 0.1	1.3 0.9 0.3 1.4 1.4 0.1 0.3 0.1 0.1	2.8 0.9 2.4 2.8 0.3 0.1 0.1 0.4	8.7 3.2 0.5 4.0 3.2 0.2 1.9 1.4 1.1	17.4 8.8 0.8 6.6 4.6 1.2 4.0 1.9 2.9	28.8 12.9 0.8 7.8 11.7 1.0 5.3 2.5 1.4	33.9 14.5 2.5 13.8 18.4 1.8 10.1 2.8 5.1	55.3 23.5 2.1 18.3 24.2 3.5 15.2 4.1 3.5	71.2 33.4 1.6 27.0 38.8 7.0 24.3 4.9 4.3	53.7 16.6 2.6 19.6 31.0 5.7 14.0 2.2 3.5).6 2.5).8	3.3 0.3 3.0 3.8 0.5 2.1 0.6	0.47 0.21 0.02 0.19 0.22 0.02 0.12 0.05 0.06	1.10 0.49 0.04 0.42 0.54 0.08 0.32 0.09 0.10	8.4 3.6 0.4 3.3 4.1 0.6 2.4 0.7 0.8	C15 C16 C17 C18 C19-20 C21 C22 C23-24 C25
Nose, sinuses etc. Larynx Trachea, bronchus and lung Other thoracic organs	82 571 1156 34	0 0 3 0	0			0.1	0.1 0.1 0.3 0.1	0.1 0.7 0.3	0.6 0.5 0.7	0.6 1.0 1.6 0.1	0.6 1.0 4.1 0.1	0.8 5.5 9.4 0.3	1.7 11.3 19.6 0.5	1.4 17.6 36.6 1.0	2.5 27.9 55.1 0.5	6.2 31.8 81.5 1.4	6.5 44.2 78.2 0.5	2.2 27.9 52.8 0.4	1		9.8	0.04 0.33 0.64 0.02	0.10 0.71 1.44 0.03	0.8 5.3 10.7 0.3	C30-31 C32 C33-34 C37-38
Bone Melanoma of skin Other skin	85 54 257	0 0 0	0		0.		1.2 0.4	0.4	0.9 0.2 0.5	0.1 0.4 1.6	0.4	0.6 1.1 3.2	0.5 0.5 4.7	0.6 1.2 6.8	1.4 2.1 10.4	1.4 2.8 9.3	1.1 2.7 16.2	1.7 3.9 16.2	().8).5 2.6	0.5	0.05 0.03 0.15	0.06 0.06 0.28	0.8 0.5 2.4	C40-41 C43 C44
Mesothelioma Kaposi sarcoma Connective and soft tissue	6 1 117	0 0 0	0	2 0.	3 0,4	0.6	0.5	0.5	1.4	0.1 0.1 0.7	1.3	1.6	0.3	2.3	0.2	0.3	5.9	0.4	(0.0	0.00	0.01 0.00 0.11	0.1 0.0 1.1	C45 C46 C47.C49
Breast Penis Prostate Testis Other male genital organs	69 97 791 54 11	1 0 2 0 0	0	9 0.	2 -	0.2	0.5	0.1	0.4 0.1 0.9	0.4 0.3 0.3 0.6	0.9 1.2 0.1 0.7	0.8 1.3 0.6 0.2 0.2	1.3 2.2 3.4 0.3 0.2	1.6 2.7 11.0 0.4 0.2	2.1 3.2 26.0 1.2 0.5	2.8 4.1 57.4 0.3 0.7	5.4 4.9 94.9 -	4.4 6.1 109.1 0.4 0.4		1.9).5	0.8 6.7 0.5	0.04 0.06 0.21 0.04 0.00	0.08 0.10 0.97 0.04 0.02	0.6 0.9 7.5 0.5 0.1	C50 C60 C61 C62 C63
Kidney Renal pelvis Ureter Bladder Other urinary organs	217 4 1 442 4	0 0 1 0	0	90.	1 0.	0.1	0.1	0.3	0.7	1.9 - 1.1	1.8 - 1.5	1.9 - 3.3	4.2 0.3 6.4	6.1 - 11.5	8.5 0.2 0.2 18.2 0.2	10.0 0.3 27.6 0.3	12.4 35.0	7.0 - 33.6 0.9).0 1.4	0.0 0.0 3.8	0.13 0.00 0.00 0.21 0.00	0.25 0.00 0.00 0.53 0.00	2.0 0.0 0.0 4.1 0.0	C64 C65 C66 C67 C68
Eye Brain, nervous system Thyroid Adrenal gland Other endocrine	23 217 310 14 4	0 1 0 0 0	1. 1. 0	0 1.	8 0. 0.	1.2	0.7 2.9 0.1 0.1	0.7 2.5 0.1	0.2 2.3 4.1	0.1 2.0 5.1	3.6 4.7	0.2 2.4 4.6	4.2 4.6	3.3 5.5 0.2	0.2 5.3 6.0 0.5 0.2	4.5 5.5 0.7	6.5 8.1	1.3 3.1 7.0).1	1.8 2.6 0.1	0.01 0.14 0.21 0.01 0.00	0.01 0.20 0.27 0.01 0.00	0.3 2.0 2.8 0.2 0.0	C69 C70-72 C73 C74 C75
Hodgkin disease Non-Hodgkin lymphoma Immunoproliferative diseases Multiple myeloma	104 479 3 207	0 2 0 0		3 1.	0 1.	1.3	2.2	0.9	1.1 1.5 0.2	0.6 2.4 0.1	1.5 3.1 0.1	1.0 5.7 0.2 2.2	1.9 7.6 4.2	0.4 8.8 6.3	2.5 17.5 0.2 8.3	2.1 21.1 13.8	2.7 23.7 16.2	3.5 24.4 0.4 11.3		4.8 0.0 2.1	4.1 0.0 1.8		0.09 0.50 0.00 0.26	1.0 4.5 0.0 1.9	C81 C82-85,C90 C88 C90
Lymphoid leukaemia Myeloid leukaemia Leukaemia unspecified Myeloproliferative disorders Myelodysplastic syndromes	206 244 16 4 17	0 0 0 0	40	8 0.		5 1.4	0.9 1.6 0.1	0.9 1.3 0.1	1.6 1.5 0.5	0.6	1.5	1.1 4.0 0.2	1.0 3.0 - -	1.6 4.3 0.2 0.2 0.2	1.6 5.8 0.5 1.2	4.5 9.3 1.7 - 0.3	1.6 6.5 0.5 2.2	3.9 10.5 - 1.3).2).0	2.1 0.1 0.0	0.12 0.14 0.01 0.00 0.01	0.15 0.22 0.02 0.01 0.02	2.2 2.3 0.2 0.0 0.2	C91 C92-94 C95 MPD MDS
Other and unspecified All sites	793 12021	5 29	0	2 0.			0.3 15.3	1.2 15.6	1.0 27.8	1.1 37.6	4.6 68.9	9.4 124.8	16.4 217.3	20.2 308.1	29.0 441.0	46.3 629.8	52.8 803.3	44.5 672.2		1.9		0.42	0.92	7.4	O&U ALL
All sites but C44	11764	29	12	9 10.	7 9.) 11.5	14.9	15.2	27.3	36.0	67.1	121.6	212.6	301.3	430.6	620.5	787.1	656.0	110	.9 10	0.00	6.37	13.42	109.6	ALLbC44

Table 9 Age specific incidence rate, Crude incidence rate, Age standardized incidence rate per 100,000 population & Cumulative risk of cancers byfive-year age group and site among Males in Sri Lanka, 2014

, Reference population: World Standard Population

Table builtWed Mar 03 14:12:52 IST 2021 by CanReg5.

Table 10 Age specific incidence rate, Crude incidence rate, Age standardized incidence rate per 100,000 population & Cumulative risk of cancers byfive-year age group and site among Females in Sri Lanka,2014

Sri Lanka Cancer Registry 2014																							
							Inciden	ce per 1	00,000	by age g	group (F	Period) -	Female	•									
SITE	ALL A		0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75+	CRUDE RATE		M CUM 64 0-74	ASR	ICD (10th)
Lip Tongue Mouth Salivary glands Tonsil Other oropharynx Nasopharynx Hypopharynx	14 138 377 58 14 16 11 72		0.1	-	-	0.2	0.2 0.2 0.4	0.1 0.2 0.2 0.2	0.5 0.3 0.6 0.1	0.7 0.5 0.4	0.7 2.0 0.7 0.3 0.1	0.1 1.6 3.4 0.7 0.1 0.3 0.6	0.2 3.2 6.0 1.1 0.3 0.3	0.5 2.8 8.4 1.2 0.3 0.3 1.4	1.0 4.2 9.2 1.6 0.4 0.2 0.6 3.6	0.3 4.5 19.1 1.4 0.6 0.8 - 4.2	5.5 24.2 2.1 0.9 2.6 4.3	0.9 7.4 20.4 0.9 0.3 0.3 2.7	0.1 1.3 3.5 0.5 0.1 0.1 0.1 0.1	1.1 0. 2.9 0. 0.4 0. 0.1 0. 0.1 0. 0.1 0. 0.1 0. 0.6 0.	01 0.01 07 0.12 15 0.37 03 0.05 01 0.01 01 0.02 01 0.01 03 0.08	0.1 1.0 2.9 0.5 0.1 0.1 0.1 0.6	C00 C01-02 C03-06 C07-08 C09 C10 C11 C12-13
Pharynx unspecified Oesophagus Stomach Small intestine Colon Rectum Anus Liver Gallbladder etc. Pancreas	22 712 219 40 471 494 39 87 91 73	0 2 0 2 0 0 1 0 1	0.3	0.2	0.1	0.1	0.2	0.1	0.2 0.1 0.1 1.4 1.4 0.3 0.1	0.8 0.5 2.4 2.4 0.1 0.7 0.5	1.5 1.4 0.1 4.1 3.8 0.1 0.3 0.4 0.7	0.3 5.1 1.0 0.6 5.1 5.7 - 0.7 1.0	0.5 10.9 4.6 0.8 7.5 8.8 0.5 1.4 2.8 0.5	0.2 13.9 5.2 2.3 12.0 13.0 1.0 1.4 1.9 1.7	0.8 26.5 5.4 1.0 13.1 15.3 1.2 2.8 3.4 2.4	0.6 32.3 12.3 1.1 15.4 21.6 2.5 4.5 2.8 3.6	2.6 46.8 12.3 2.1 23.4 21.3 3.4 7.7 6.0 3.0	1.2 43.4 9.7 0.3 19.8 17.4 1.8 3.0 2.1 3.0	0.2 6.6 2.0 0.4 4.4 4.6 0.4 0.8 0.8 0.8 0.8	5.5 0. 1.7 0. 0.3 0. 3.6 0. 3.8 0. 0.3 0. 0.7 0. 0.7 0.	01 0.02 30 0.69 09 0.22 02 0.04 24 0.43 25 0.47 01 0.04 03 0.10 05 0.09 04 0.07	0.2 5.4 1.7 0.3 3.6 3.8 0.3 0.7 0.7 0.7	C14 C15 C16 C17 C18 C19-20 C21 C22 C23-24 C25
Nose, sinuses etc. Larynx Trachea, bronchus and lung Other thoracic organs	31 51 325 20	0 0 1 0	0.1 0.1 0.1	0.1	-	-	0.4	0.4 0.1	0.2	0.3 0.3 2.2	0.3 0.1 2.2 0.3	0.4 0.1 3.8 0.6	0.5 1.1 5.4 0.2	0.7 1.2 8.0 0.7	1.8 2.2 12.7 0.8	3.6 10.9 0.3	1.3 2.6 16.2	0.6 0.6 9.7 0.6	0.3 0.5 3.0 0.2	0.4 0.	02 0.03 03 0.06 18 0.31 01 0.02	0.2 0.4 2.5 0.2	C30-31 C32 C33-34 C37-38
Bone Melanoma of skin Other skin	61 43 192	0 0 1	0.1	0.3	1.3	1.5 0.4	0.1	0.5 0.1 0.1	0.3	0.1	0.3	0.3 0.3 1.8	0.9 0.8 4.6	0.3 0.7 3.3	1.0 1.2 5.2	0.6 1.7 6.5	1.3 2.6 12.3	0.6 3.2 12.7	0.6 0.4 1.8	0.3 0	04 0.05 02 0.04 08 0.17	0.6 0.3 1.5	C40-41 C43 C44
Mesothelioma Kaposi sarcoma Connective and soft tissue	3 0 119	0 0 1	1.2	0.6	0.2	0.4	0.5	0.5	0.5	1.2	1.5	· _	1.7	0.2	0.2	2.2	0.4	1.8	0.0 0.0 1.1	0.0 0.	00 0.00 00 0.00 07 0.09	0.0 0.0 1.0	C45 C46 C47,C49
Breast Vulva Vagina Cervix uteri Corpus uteri Uterus unspecified <i>Ovary</i> Other female genital organs Placenta	3291 44 62 1090 562 98 <i>951</i> 30 10	6 0 0 0 0 0 0 1 0	0.1	0.2	0.6	0.1	1.2 - - 2.5 0.1	3.4 0.2 0.5 0.1 2.3 0.2	9.8 0.2 0.9 1.3 0.1 3.8 - 0.3	24.8 0.3 4.7 0.9 3.8 	45.7 0.3 - 9.3 2.2 1.1 9.7 0.3 0.1	65.0 0.1 0.6 18.8 3.1 1.3 14.1 0.7 0.1	77.7 0.5 0.9 25.8 11.5 2.9 24.7 1.4 0.2	85.9 1.4 1.2 28.7 21.4 1.7 26.8 0.9	88.6 0.8 1.6 33.8 24.7 3.6 25.7 0.6	96.2 1.1 2.5 37.6 26.4 4.8 26.9 0.6	95.7 0.9 2.6 41.7 25.5 3.8 30.2 0.9	58.7 4.7 5.3 33.6 8.9 2.1 15.9 0.3	30.7 0.4 0.6 10.2 5.2 0.9 8.9 0.3 0.1	0.3 0. 0.5 0. 8.3 0. 4.3 0. 0.8 0. 7.3 0. 0.2 0.	01 2.98 02 0.03 02 0.05 61 1.01 33 0.59 05 0.10 58 0.87 02 0.03 01 0.01	26.0 0.3 0.5 8.5 4.4 0.8 7.6 0.2 0.1	C50 C51 C52 C53 C54 C55 C56 C56 C57 C58
Kidney Renal pelvis Ureter Bladder Other urinary organs	78 2 4 108 0	0 0 0 0	0.1	0.2	-	0.1 - - -	-	0.2	0.1 - - -	0.3 0.1 0.1	0.8	0.6 - 0.7	1.2 0.2 1.1	1.7 0.2 2.3	1.6 0.2 3.4	2.0 5.3	4.3 6.4	2.1 0.6 7.1	0.7 0.0 0.0 1.0 0.0	0.0 0. 0.0 0. 0.8 0.	04 0.07 00 0.00 00 0.00 04 0.10 00 0.00	0.7 0.0 0.0 <i>0.8</i> 0.0	C64 C65 C66 C67 C68
Eye Brain, nervous system Thyroid Adrenal gland Other endocrine	29 161 1432 15 3	0 0 5 0 0	2.0 0.6 1.0	0.1 1.2 0.2	1.4 1.2	0.8 4.6	0.9 7.8	0.5 14.3	1.7 23.0	0.7 28.3	1.8 28.5	0.1 2.3 20.4 0.3	0.2 2.0 23.0 0.2 0.2	0.5 3.0 12.7 0.2	0.4 3.0 16.7 0.2 0.2	0.3 1.7 14.0	0.4 3.8 23.4	0.3 1.8 10.0 0.3	0.3 1.5 13.4 0.1 0.0	1.2 0. 11.0 0. 0.1 0.	02 0.02 10 0.13 91 1.10 01 0.01 00 0.00	0.3 1.4 11.8 0.2 0.0	C69 C70-72 C73 C74 C75
Hodgkin disease Non-Hodgkin lymphoma Immunoproliferative diseases Multiple myeloma	74 331 2 185	0 0 0 0	0.7	0.2	0.2	1.0 1.2 -	1.6 0.9 -	1.2	0.5 0.5 -	0.8 1.6 - 0.1	0.4	0.6 5.7 1.8	0.8 4.1 4.5	0.9 3.5 4.7	1.0 10.4 7.2	0.8 12.3 0.6 7.9	0.4 16.6 11.1	1.5 9.7 6.5	0.7 3.1 0.0 1.7	2.5 0. 0.0 0. 1.4 0.	04 0.05 17 0.31 00 0.00 09 0.19	0.6 2.7 0.0 1.4	C81 C82-85,C96 C88 C90
Lymphoid leukaemia Myeloid leukaemia Leukaemia unspecified Myeloproliferative disorders Myelodysplastic syndromes	116 194 8 6 25	0 0 0 0	3.3 0.6 0.1	1.8 0.1 - -	1.8 0.4 - 0.1	0.6 0.8 0.1	0.2 0.6 - -	1.1 - -	0.2 1.4 - - 0.2	0.3 2.0 0.1	1.1 1.7 0.1	0.3 2.9 - - 0.1	1.1 3.2 0.2 0.3 0.3	0.7 2.4 0.3 -	1.4 3.8 0.2 0.4 0.8	1.1 4.5 0.3 1.4	2.1 7.7 - 1.3	2.4 5.0 0.3 1.8	1.1 1.8 0.1 0.1 0.2	1.5 0. 0.1 0.	06 0.08 11 0.17 01 0.01 00 0.00 01 0.02	1.2 1.6 0.1 0.0 0.2	C91 C92-94 C95 MPD MDS
Other and unspecified All sites	546 13250	4 25	0.6	0.2 5.8	8.0	0.1 14.4	0.1	0.2 30.3	1.6 52.7	1.9 84.7	3.4 131.5	6.0 181.6	11.5 264.8	9.0 295.1	19.3 369.5	21.6 423.3	28.9 514.2	20.4 363.3	5.1 123.6		27 0.53	4.3	O&U ALL
All sites All sites but C44	13250	25	12.8	5.8	8.0 8.0	14.4	18.3 18.3	30.3	52.7	84.7	131.5	181.6	264.8	295.1 291.8	364.3	425.5	514.2	350.6			36 12.06 28 11.88		ALL ALLbC44
, Reference population: Work									builtWee														

, Reference population: World Standard Population

	Site Group		ICD O - 3 Histology	Male	Female	Total
	Leukaemias, myeloproliferative diseases, and myelodysplastic diseases					
(a)	Lymhoid leukaemias	9826	Burkitt cell leukemia	3	1	4
		9835	Precursor cell lymphoblastic leukemia, NOS	43	22	65
		9836	Precursor B-cell lymphoblastic leukemia	51	35	86
		9837	Precursor T-cell lymphoblastic leukemia	15	7	22
(b)	Acute myeloid leukaemias	9840	Acute myeloid leukemia, M6 type	1	0	1
		9861	Acute myeloid leukemia, NOS	13	7	20
		9866	Acute promyelocytic leukemia, t(15;17)(q22;q11-	0	2	2
		9872	Acute myeloid leukemia, minimal differentiation	0	1	1
		9874	Acute myeloid leukemia with maturation	4	3	7
		9891	Acute monocytic leukemia	2	1	2
		9910	Acute megakaryoblastic leukemia	1	0	1
(c)	Chronic myeloproliferative diseases	9863	Chronic myeloid leukemia, NOS	3	0	3
		9875	Chronic myelogenous leukaemia, BCR/ABL positive	1	1	2
(d)	Myelodysplastic syndrome and other myeloproliferative diseases	9945	Chronic myelomonocytic leukemia, NOS	2	0	2
		9946	Juvenile myelomonocytic leukemia	2	0	2
		9983	Refractory anemia with excess blasts		1	1
		9989	Myelodysplastic syndrome, NOS	1	0	1
(e)	Unspecified and other specified leukaemias	9800	Leukemia, NOS	2	2	2
		9801	Acute leukemia, NOS	1	0	1
		9930	Myeloid sarcoma	0	1	1
	Total			145	84	22
I	Lymphoma and reticuloendothelial neoplasms					
(a)	Hodgkin lymphomas	9650	Hodgkin lymphoma, NOS	4	4	8
		9651	Hodgkin lymphoma, lymphocyte-rich	1	1	2

Table 11 Childhood cancer incidence data in Sri Lanka (0-19 years) - 2014

	Site Group		ICD O - 3 Histology	Male	Female	Total
		9652	Hodgkin lymphoma, mixed cellularity, NOS	2	0	2
		9659 9663	Hodgkin lymphoma, nodular lymphocyte predominan Hodgkin lymphoma,	1 0	0 5	1 5
(b)	Non-Hodgkin lymphomas	9591	nodular sclerosis, NOS Malignant lymphoma, non- Hodgkin, NOS	7	6	13
		9680	Malignant lymphoma, large B-cell, diffuse, NOS	5	0	5
		9690	Follicular lymphoma, NOS	1	0	1
		9700	Mycosis fungoides	0	1	1
		9702	Mature T-cell lymphoma, NOS	1	1	2
		9714	Anaplastic large cell lymphoma, T cell and	4	0	4
		9727	Precursor cell lymphoblastic lymphoma, NOS	5	5	10
		9729	Precursor T-cell lymphoblastic lymphoma	3	1	4
(c)	Burkitt lymphoma	9687	Burkitt lymphoma, NOS	6	1	7
(d)	Miscellaneous lymphoreticular neoplasms	9750	Malignant histiocytosis	2	0	2
		9754	Langerhans cell histiocytosis, disseminated	7	6	13
	Total			49	31	80
III	CNS and miscellaneous intracranial and intraspinal neoplasms					
(a)	Ependymomas and choroid plexus tumours	9391	Ependymoma, NOS	1	3	4
		9392	Ependymoma, anaplastic	1	0	1
(b)	Astrocytomas	9380	Glioma, malignant	0	2	2
		9400	Astrocytoma, NOS	7	8	15
		9411	Gemistocytic astrocytoma	0	1	1
		9420	Fibrillary astrocytoma	3	1	4
		9440	Glioblastoma, NOS	2	2	4
		9441	Giant cell glioblastoma	0	1	1
(c)	Intracranial and intraspinal embrayonal tumours	9470	Medulloblastoma, NOS	10	7	17
		9471	Desmoplastic nodular medulloblastoma	2	0	2

Table 11 Childhood cancer incidence data in Sri Lanka (0-19 years) - 2014

		1				
	Site Group		ICD O - 3 Histology	Male	Female	Total
		9473	Primitive neuroectodermal tumor, NOS	1	0	1
(d)	Other gliomas	9380	Glioma, malignant	4	5	9
		9450	Oligodendroglioma, NOS	2	0 5 1 1 2 1 35 0 14 0 14 0 14 0 14 18 13 13 1 1 1 1 1 5 3 1 1 1 1 1 1 1 5 3 1 1 1 1	3
		9451	Oligodendroglioma, anaplastic	1	1	2
(e)	Other specified intracranial and intraspinal neoplasms	9530	Meningioma, malignant	0	2	2
(f)	Unspecified intracranial and intraspinal neoplasms	8000	Neoplasm, malignant	1	1	2
	Total			35	35	70
IV	Neuroblastoma and other peripheral nervous cell tumours					
(a)	Neuroblastoma and ganglioneuroblastoma	9490	Ganglioneuroblastoma	2	0	2
		9500	Neuroblastoma, NOS	12	14	26
(b)	Other peripheral nervous cell tumours	9522	Olfactory neuroblastoma	1	0	1
	Total			15	14	29
V	Retinoblastoma, NOS	9510	Retinoblastoma, NOS	14		32
	Total			14	18	32
VI	Renal tumours					
(a)	Nephroblastoma and other nonepithelial renal tumours	8960	Nephroblastoma, NOS	9	13	22
		8964	Clear cell sarcoma of kidney	1	1	2
(b)	Renal carcinoma	8010	Carcinoma, NOS	0	1	1
				0		-
	Total			10		25
VII	Total Hepatic tumours					
VII (a)		8970	Hepatoblastoma		15	
	Hepatic tumours Hepatoblastoma Hepatic carcinomas	8970 8170		10	15 3	25
(a) (b)	Hepatic tumours Hepatoblastoma Hepatic carcinomas Total		Hepatoblastoma Hepatocellular carcinoma,	10 7	15 3 1	25 10
(a) (b) VIII	Hepatic tumours Hepatoblastoma Hepatic carcinomas Total Malignant bone tumours	8170	Hepatoblastoma Hepatocellular carcinoma, NOS	10 7 1 8	15 3 1 4	25 10 2 12
(a) (b)	Hepatic tumours Hepatoblastoma Hepatic carcinomas Total	8170 9180	Hepatoblastoma Hepatocellular carcinoma, NOS Osteosarcoma, NOS	10 7 1 8 19	15 3 1 4 17	25 10 2 12 36
(a) (b) VIII	Hepatic tumours Hepatoblastoma Hepatic carcinomas Total Malignant bone tumours	8170	Hepatoblastoma Hepatocellular carcinoma, NOS Osteosarcoma, NOS Chondroblastic	10 7 1 8	15 3 1 4	25 10 2 12
(b) VIII	Hepatic tumours Hepatoblastoma Hepatic carcinomas Total Malignant bone tumours	8170 9180	Hepatoblastoma Hepatocellular carcinoma, NOS Osteosarcoma, NOS	10 7 1 8 19	15 3 1 4 17	25 10 2 12 36

		Site Group		ICD O - 3 Histology	Male	Female	Total
(b)	Chondrosarcomas	9242	Clear cell chondrosarcoma	0	1	1
(c	c)	Ewing tumour and related sarcomas of bone	9260	Ewing sarcoma	13	6	19
(d	1)	Other specified malignant bone tumours	9270	Odontogenic tumor, malignant	1	0	1
(e	e)	Unspecified malignant bone tumours	8000	Neoplasm, malignant	1	1	2
		Total			36	28	64
IX		Soft tissue and other extraosseous sarcomas				20	04
(a	a)	Rhabdomyosarcomas	8900	Rhabdomyosarcoma, NOS	5	2	7
(u	~)		8910	Embryonal rhabdomyosarcoma, NOS	5	7	12
			8991	Embryonal sarcoma	1	1	2
(b))	Fibrosarcomas, peripheral nerve sheath tumours, and other fibrous neoplasms	8810	Fibrosarcoma, NOS	0	1	1
			8814	Infantile fibrosarcoma	0	2	2
			9540	Malignant peripheral nerve sheath tumor	0	2	2
			9580	Granular cell tumor, malignant	0	1	1
(d	1)	Other specified soft tissue sarcomas	8806	Desmoplastic small round cell tumor	2	0	2
			8832	Dermatofibrosarcoma, NOS	1	0	1
			9040	Synovial sarcoma, NOS	1	0	1
			9041	Synovial sarcoma, spindle cell	1	1	2
			9364	Peripheral neuroectodermal tumor	1	0	1
(e	e)	Unspecified soft tissue sarcomas	8800	Sarcoma, NOS	1	3	4
			8802	Giant cell sarcoma (except of bone)	0	1	1
		Total			18	21	39
X		Germ cell tumours, trophoblastic tumours, and neoplasms of gonads					
(a	a)	Intracranial and intraspinal germ cell tumours	9064	Germinoma	2	0	2
			9080	Teratoma, malignant, NOS	0	1	1
(b))	Malignant extracranial and extragonadal germ cell tumours	9064	Germinoma	1	0	1

		Site Group		ICD O - 3 Histology	Male	Female	Total
			9085	Mixed germ cell tumor	2	1	3
	(c)	Malignant gonadal germ cell tumours	9060	Dysgerminoma	0	5	5
	(0)	Manghant gonadar gorni con tambars		Germinoma	0		
			9064 9070	Embryonal carcinoma, NOS	0	2 1	2 1
			9070 9071	Yolk sac tumor	9	6	15
			9080	Teratoma, malignant, NOS	9	1	15
			9080	Mixed germ cell tumor	2	4	6
			7005	winked gerin een tuinor	2		0
	(e)	Other and unspecified malignant gonadal tumours	8004	Malignant tumor, spindle cell type	1	0	1
			8620	Granulosa cell tumor, malignant	0	1	1
			8631	Sertoli-Leydig cell tumor, poorly differentiate	0	1	1
		Total			19	25	44
XI		Other malignant epithelial neoplasms and malignant melanomas					
	(a)	Adrenocortical carcinomas	8370	Adrenal cortical carcinoma	2	1	3
	(b)	Thyroid carcinomas	8050	Papillary carcinoma, NOS	1	0	1
			8260	Papillary adenocarcinoma, NOS	7	28	35
			8330	Follicular adenocarcinoma, NOS	0	6	6
			8335	Follicular carcinoma, minimally invasive	0	1	1
			8340	Papillary carcinoma, follicular variant	1	10	11
			8341	Papillary microcarcinoma	1	3	4
			8510	Medullary carcinoma, NOS	0	1	1
	(d)	Malignant melanomas	8720	Malignant melanoma, NOS (except juvenile melano	2	0	2
	(e)	Skin carcinomas	8070	Squamous cell carcinoma, NOS	0	1	1
			8074	Squamous cell carcinoma, spindle cell	1	0	1
			8090	Basal cell carcinoma, NOS	0	1	1
			8430	Mucoepidermoid carcinoma	0	1	1
	(f)	Other and unspecified carcinomas	8010	Carcinoma, NOS	1	0	1
			8041	Small cell carcinoma, NOS	1	0	1
			8070	Squamous cell carcinoma, NOS	1	1	2

	Site Group		ICD O - 3 Histology	Male	Female	Total
		8130	Papillary transitional cell carcinoma	0	1	1
		8140	Adenocarcinoma, NOS	1	4	5
		8200	Adenoid cystic carcinoma	0	1	1
		8240	Carcinoid tumor, NOS	0	1	1
		8246	Neuroendocrine carcinoma, NOS	2	4	6
		8430	Mucoepidermoid carcinoma	9	3	12
		8490	Signet ring cell carcinoma	1	0	1
	Total			31	68	99
XII	Other and unspecified malignant neoplasms					
(a)	Other specified malignant tumours	8973	Pleuropulmonary blastoma	0	1	1
(b)	Other unspecified malignant tumours	8000	Neoplasm, malignant	5	7	12
		8004	Malignant tumor, spindle cell type	1	0	1
	Total			6	8	14

Cancer Mortality Data of Sri Lanka

Mortality data due to cancers were obtained through;

- (i) Annual Health Bulletin based on Indoor Morbidity Mortality Return (IMMR) from the hospital statistics and
- (ii) Department of Census & Statistics website based on data derived from the vital registration system of Sri Lanka

Table 12 Deaths due to cancers in hospitals in Sr.	i Lanka, 2005 - 2014
--	----------------------

Year	No. of hospital deaths	Crude hospital annual death rate due to	Proportionate Mortality Ratio
	due to cancers	cancers per 100,000 population	(PMR) out of all hospital deaths
2005	2753	14.0	8.3
2006	3241	16.3	9.9
2007	3498	17.5	10.1
2008	3485	17.2	9.8
2009	3774	18.5	10.0
2010	4449	21.5	11.1
2011	4631	22.2	11.8
2012	4519	22.2	11.6
2013	4539	22.2	11.2
2014	4995	24.0	11.7

Sources: Annual Health Bulletin 2005 to 2014

Year	Population	Cancer deaths				
	ropulation	No.	CR	PMR (%)		
2001	18,797,000	8,063	42.9	7.1		
2002	18,921,000	7,986	42.2	7.1		
2003	19,173,000	8,396	43.8	7.3		
2004	19,435,000	9,127	47.0	7.9		
2005	19,644,000	9,403	47.9	7.1		
2006	19,958,000	10,386	52.3	8.8		
2007	20,039,000	10,631	53.1	8.9		
2008*	20,246,000					
2009	20,450,000	11,286	55.2	8.8		
2010	20,653,000	11,836	57.3	9.1		
2011	20,892,000	12,267	58.7	10.0		
2012	20,359,439	12,581	61.8	10.2		
2013	20,585,041	12,954	62.9	10.2		
2014	20,777,595	13,514	65.0	10.5		

Table 13 Deaths due to cancers out of all registered deaths in hospitals & field in Sri Lanka, 2001 - 2014

Source: Department of Census & Statistics, Sri Lanka * Not published

CR-Crude annual death rate due to cancers per 100,000 population PMR – Proportionate Mortality Ratio out of total deaths

Table 14 Proportion of deaths due to cancers occurred at the hospitals out of total cancer deaths

Year	Total cancer deaths	Hospital cancer deaths	% of hospital cancer deaths
2010	11836	4449	37.6
2011	12267	4631	37.8
2012	12581	4519	35.9
2013	12954	4539	35.0
2014	13514	4995	37.0

Year		Male			Female	;
	No.	CR	ASR	No.	CR	ASR
2001	4375	46.7	52.1	3688	39.1	39.9
2002	4350	46.5	51.2	3636	37.9	38.6
2003	4614	48.7	53.6	3782	38.9	39.6
2004	4942	57.1	57.3	4185	42.9	44.0
2005	4983	50.9	57.0	4420	44.8	45.8
2006	5644	57.1	63.6	4742	47.6	48.7
2007	5827	58.5	65.4	4804	47.6	48.8
2008*						
2009	6105	60.2	67.6	5181	50.3	52.0
2010	6438	62.8	70.9	5398	51.9	53.5
2011	6641	64.0	72.5	5626	53.5	55.3
2012	6908	70.1	65.5	5673	54.0	44.4
2013	7166	71.9	67.4	5788	54.5	44.9
2014	7459	74.2	69.5	6055	56.5	46.5


Table 15 Deaths due to cancers by sex out of all registered deaths in hospitals & field in Sri Lanka, 2001 - 2014

Source: Department of Census & Statistics, Sri Lanka

* Not published

CR-Crude annual death rate due to cancers per 100,000 population

ASR – Age standardized annual death rate due to cancers per 100,000 population



Source: Department of Census & Statistics, Sri Lanka * Not published

Figure : 8 Age standardized cancer mortality rates in Sri Lanka, 2001 -2015

Type of Cancer	No	%	CR	ASR
1-034 Malignant neoplasm of trachea, bronchus and lung	902	12.6	9.1	8.5
1-027 Malignant neoplasm of lip, oral cavity and pharynx	863	12.0	8.7	8.1
1-031 Malignant neoplasm of liver and intrahepatic bile ducts	491	6.9	4.9	4.7
1-028 Malignant neoplasm of oesophagus C15	371	5.2	3.7	3.4
1-045 Leukaemia C91-C95	314	4.4	3.2	3.1
1-029 Malignant neoplasm of stomach C16	272	3.8	2.7	2.5
1-042 Malignant neoplasm of meninges, brain and other parts of central nervous	251	3.5	2.5	2.4
system				
1-030 Malignant neoplasm of colon, rectum and anus C18-C21	205	2.9	2.1	1.9
1-040 Malignant neoplasm of Prostate C61	159	2.2	1.6	1.5
1-043 Non-Hodgkins lymphoma C82-C85	154	2.1	1.5	1.4
1-026 Neoplasms C00-D48	7166	100.0	71.9	67.4

Table 16 Leading sites (ICD-10) of cancer mortality – Male Sri Lanka 2014

Table 17 Leading sites (ICD-10) of cancer mortality – Female Sri Lanka 2014

Type of Cancer	No	%	CR	ASR
1-036 Malignant neoplasm of breast	688	11.9	6.5	5.3
1-034 Malignant neoplasm of trachea, bronchus and lung	331	5.7	3.1	2.6
1-038 Malignant neoplasm of other and unspecified parts of uterus	294	5.1	2.8	2.2
1-027 Malignant neoplasm of lip, oral cavity and pharynx	289	5.0	2.7	2.1
1-045 Leukaemia C91-C95	284	4.9	2.7	2.4
1-028 Malignant neoplasm of oesophagus C15	242	4.2	2.3	1.9
1-029 Malignant neoplasm of stomach C16	234	4.0	2.2	1.8
1-042 Malignant neoplasm of meninges, brain and other parts of central nervous	220	3.8	2.1	1.8
system				
1-039 Malignant neoplasm of ovary C56	213	3.7	2.0	1.7
1-031 Malignant neoplasm of liver and intrahepatic bile ducts	207	3.6	1.9	1.6
1-030 Malignant neoplasm of colon, rectum and anus C18-C21	167	2.9	1.6	1.3
1-026 Neoplasms C00-D48	5788	100.0	54.5	44.9

Leading cancer mortality rates, 2010-2014




Figure : 9 Age standardized leading cancer mortality rates in males in Sri Lanka, 2010 - 2014





Figure : 10 Age standardized leading cancer mortality rates in females in Sri Lanka, 2010 - 2014



Mortality trends of leading cancers, 2010-2014

Figure : 11 Age standardized Trachea, bronchus & lung cancer mortality rates of Sri Lanka, 2010-2014




Figure : 12 Age standardized Lip, oral cavity & pharyngeal cancer mortality Rates of Sri Lanka, 2010 – 2014




Figure : 13 Age standardized Breast cancer mortality rates of Sri Lanka, 2010 - 2014




Figure : 14 Age standardized Oesophageal cancer mortality rates of Sri Lanka, 2010 – 2014




Figure : 15 Age standardized Colon, rectal and anal cancer mortality rates of Sri Lanka, 2010 – 2014




Figure : 16 Age standardized Prostate cancer mortality rates of Sri Lanka, 2010 - 2014




Figure : 17 Age standardized Cervical cancer mortality rates of Sri Lanka, 2010 – 2014



National Cancer Control Programme Ministry of Health 555/5 Public Health Complex Elvitigala Mawatha, Narahenpita, Colombo 05 Sri Lanka + 94 112368627 www.nccp.health.gov.lk